By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Nordic Nanovector 

Kjelsåsveien 168 B

  Oslo  0884  Norway
Phone: 47-22-18-33-01 Fax: 47-22-58-00-07


Company News
Nordic Nanovector: Increase Of Share Capital/Mandatory Notification Of Trade 7/10/2017 8:57:47 AM
Nordic Nanovector: Mandatory Notification Of Trade - Primary Insider 7/5/2017 10:45:15 AM
Nordic Nanovector: Mandatory Notification Of Trade - Primary Insider 6/22/2017 11:03:49 AM
Nordic Nanovector Release: Single Dose Betalutin Continues To Show Promising Efficacy And Safety In Recurrent Indolent NHL Patients 6/14/2017 7:01:41 AM
Nordic Nanovector Release: Invitation To Conference Call For Updated Clinical Trial Results Reported At The International Conference On Malignant Lymphoma 6/13/2017 1:02:07 PM
Nordic Nanovector To Be Included In Oslo Børs OBX Index 6/9/2017 9:00:03 AM
Nordic Nanovector Release: Accepted Abstract By ICML With Updated Results From Phase I/II Trial Of Betalutin In NHL Is Now Available On-Line 6/8/2017 6:27:34 AM
Nordic Nanovector: Allocation Of Restricted Stock Units (RSUs) To The Board Of Directors 6/2/2017 7:03:28 AM
Nordic Nanovector - Results For First Quarter 2017 5/24/2017 8:56:38 AM
Nordic Nanovector Release: Safety Review Committee Approves The Continued Evaluation Of The 20 Mbq/Kg Betalutin With 100 Mg/M2 Lilotomab Regimen In Phase ll Cohort In NHL 5/19/2017 9:32:48 AM